Late recurrence of ovarian cancer: a literature review and description of two cases

Ovarian cancer is not the most frequent malignancy of female reproductive system, but it causes many deaths in women with this diagnosis. Mostly of the patients with ovarian cancer will have recurrence after first-line standard treatment containing surgery and chemotherapy. This article presents two cases with late recurrence in women with ovarian cancer; both were nine years after the first diagnosis and both were operated and received second-line chemotherapy. The authors reviewed medical literature with late recurrence of ovarian cancer.

Ovarian cancer; Late recurrence.

[1] Song M.J., Lee S.H., Choi M.R., Son H.J., Lee C.W., Yoon J.H., et al.: “Diagnostic value of CA125 as a predictor of recurrence in advanced ovarian cancer”. Eur. J. Gynaecol. Oncol., 2013, 34, 148.

[2] Jemal A., Siegel R., Xu J., Ward E.: “Cancer statistics, 2010”. Ca Cancer J. Clin., 2010, 60, 277.

[3] Rustin G.J., Bast R.C., Kelloff G.J., Barrett J.C., Carter S.K., Nisen P.D., et al.: “Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer”. Clin. Cancer Res., 2004, 10, 3919.

[4] Weber B., Lortholary A., Mayer F., Bourgeois H., Orfeuvre H., Combe M., et al.: “Pegylated liposoma doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO Group Phase II Trial”. Ant. Canc. Res., 2009, 29, 4195.

[5] Ozols R.F.: “Update on the management of ovarian cancer”. Cancer J., 2002, 2, 22.

[6] Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J.: Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002 20(5), 1248.

[7] Markowska J., Mądry R., Kierzkowski J., Malicki J., Rodzak A., Lubin J., Bratos K.: “Radioimmunotherapy in patients with ovarian cancer in clinical remission after first line of chemotherapy proved second-line operation. - quolification to the precedure”. Ginekol. Pol., 2003, 74, 799.

[8] Vaccarello L., Rubin S.C., Vlamis V., Wong G., Jones W.B., Lewis J.L., Hoskins W.J.: Cytoreductive surgery in ovarian carcinoma patients with a documented previously complete surgical response. Gynecol. Oncol., 1995, 57, 61.

[9] Jamroż A., Rudzki S., Walczyna B.: Reccurence of ovarian cancer in extraperitoneal localization after 29th years of radical surgery. Pol. Merkur. Lekarski., 2005, 19, 545.

[10] Gadducci A., Iacconi P., Cosio S., Fanucchi A., Cristofani R., Genazzani AR.: “Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer”. Cancer Gynecol. Oncol. 2000, 79, 344.

[11] Gore M.: “Treatment of relapsed epithelal ovarian cancer”. In: ASCO Educational Book Spring. Philadelphia: Lippincott Williams and Wilkins, 2001, 468.

[12] Monk B.J., Coleman R.L.: “Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds”. Int. J. Gynecol. Cancer, 2009, 19, 63.

[13] Ozols R.F.: “Treatment goals in ovarian cancer”. Int. J. Gynecol. Cancer, 2005, 15, 3.

[14] Robinson W.R., Beyer J., Griffin S., Kanjanavaikoon P.: “Extraperitoneal metastases from recurrent ovarian cancer”. Int. J. Gynecol. Cancer, 2012, 22, 43.

[15] Rauh-Hain J.A., Guseh S.H., Esselen K.M., Growdon W.B., Schorge J.O., Horowitz N.S., et al.: Patterns of recurrence in patients treated with bevacizumab in the primary treatment of advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer, 2013, 23, 1219.

[16] Von Georgi R., Schubert K., Grant P., Münstedt K., et al.: Post-therapy surveillance and after-care in ovarian cancer. Eur J Obstet Gynecol Reprod Biol. 2004, 15, 114(2), 228.

[17] Buller R.E., Skilling J.S., Sood A.K., Plaxe S., Baergen R.N., Lager D.J.: “Field cancerization: why late “recurrent” ovarian cancer is not recurrent”. Am. J. Obstet. Gynecol., 1998, 178, 641.

[18] Makarewicz H., Emerich J., Olszewski J.: “The late recurrence of ovarian cancer seventeen years after radical surgery”. Ginekol. Pol., 2002, 73, 861.

[19] Penson R.T., Dignan F., Seiden MV., Lee H., Gallagher C.J., Matulonis U.A., et al.: Attitudes to chemotherapy in patients with ovarian cancer. Gynecol Oncol. 2004, 94, 427.

[20] Rustin G.J., van der Burg M.E., Griffin C.L., Guthrie D., Lamont A., Jayson G.C., et al.: “Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial”. Lancet, 2010, 376, 1155.

[21] Markman M.: “Optimal management of recurrent ovarian cancer”. Int. J. Gynecol. Cancer, 2009, 19, 40.

[22] Pfisterer J., Plante M., Vergote I., du Bois A., Hirte H., Lacave A.J., et al.: “Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG”. J. Clin. Oncol., 2006, 24, 4699.

[23] Jänicke F., Hölscher M., Kuhn W., von Hugo R., Pache L., Siewert JR., Graeff H.: “Radical surgical procedure improves survival time in patients with recurrent ovarian cancer”. Cancer, 1992, 70, 2129.

[24] Olszewska A., Stukan M., Emerich J.: “Clinical analysis of patients with recurrences of borderline ovarian tumors including surgical treatment”. Ginekol. Pol., 2005, 76, 782.